Sonelokimab shows promise in Phase II psoriasis trial
In the trial, 57 percent of patients with moderate to…
In the trial, 57 percent of patients with moderate to severe psoriasis treated with 120mg of sonelokimab achieved total skin clearance in 24 weeks.